A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer

Nagio Takigawa, Katsuyuki Kiura, Katsuyuki Hotta, Shinobu Hosokawa, Naoyuki Nogami, Keisuke Aoe, Kenichi Gemba, Keiichi Fujiwara, Shingo Harita, Mitsuhiro Takemoto, Kengo Himei, Tetsu Shinkai, Yoshirou Fujiwara, Saburo Takata, Masahiro Tabata, Susumu Kanazawa, Mitsune Tanimoto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

S-1, an oral 5-fluorouracil derivative, is effective against advanced non-small cell lung cancer (NSCLC) with mild toxicity and synergistic effects with radiation in preclinical trials. In this phase I study, we evaluated the dose-limiting toxicity and recommended dose of S-1 for a future phase II study when administered concurrently with thoracic radiation (total dose of 60Gy at 2Gy per daily fraction) in elderly patients (>75 years old) with localized advanced NSCLC. S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m2/day. Twenty-two previously untreated patients were enrolled in this study. Dose-limiting toxicity included febrile neutropenia, thrombocytopenia, stomatitis, and pneumonitis. One patient had grade 5 radiation pneumonitis. No other patient experienced radiation pneumonitis or esophagitis exceeding grade 2. The recommended dose for S-1 was determined to be 80mg/m2/day, which produced an overall response rate of 75% (n=12). The median progression-free survival time was 11.5 months (95% confidence interval: 7.1-15.8 months) with a median follow-up time of 27.9 months. These results indicate that concurrent treatment with S-1 and thoracic radiation is a feasible option for NSCLC in the elderly. A phase II study is currently under way.

Original languageEnglish
Pages (from-to)60-64
Number of pages5
JournalLung Cancer
Volume71
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Thorax
Radiation Pneumonitis
Radiation
Febrile Neutropenia
Stomatitis
Esophagitis
Radiation Effects
Fluorouracil
Thrombocytopenia
Disease-Free Survival
Pneumonia
Confidence Intervals
Therapeutics

Keywords

  • Elderly
  • Non-small cell lung cancer
  • Radiation
  • S-1

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer. / Takigawa, Nagio; Kiura, Katsuyuki; Hotta, Katsuyuki; Hosokawa, Shinobu; Nogami, Naoyuki; Aoe, Keisuke; Gemba, Kenichi; Fujiwara, Keiichi; Harita, Shingo; Takemoto, Mitsuhiro; Himei, Kengo; Shinkai, Tetsu; Fujiwara, Yoshirou; Takata, Saburo; Tabata, Masahiro; Kanazawa, Susumu; Tanimoto, Mitsune.

In: Lung Cancer, Vol. 71, No. 1, 01.2011, p. 60-64.

Research output: Contribution to journalArticle

Takigawa, N, Kiura, K, Hotta, K, Hosokawa, S, Nogami, N, Aoe, K, Gemba, K, Fujiwara, K, Harita, S, Takemoto, M, Himei, K, Shinkai, T, Fujiwara, Y, Takata, S, Tabata, M, Kanazawa, S & Tanimoto, M 2011, 'A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer', Lung Cancer, vol. 71, no. 1, pp. 60-64. https://doi.org/10.1016/j.lungcan.2010.04.012
Takigawa, Nagio ; Kiura, Katsuyuki ; Hotta, Katsuyuki ; Hosokawa, Shinobu ; Nogami, Naoyuki ; Aoe, Keisuke ; Gemba, Kenichi ; Fujiwara, Keiichi ; Harita, Shingo ; Takemoto, Mitsuhiro ; Himei, Kengo ; Shinkai, Tetsu ; Fujiwara, Yoshirou ; Takata, Saburo ; Tabata, Masahiro ; Kanazawa, Susumu ; Tanimoto, Mitsune. / A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer. In: Lung Cancer. 2011 ; Vol. 71, No. 1. pp. 60-64.
@article{b0001a0b9952411b85e6e065d4f63b30,
title = "A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer",
abstract = "S-1, an oral 5-fluorouracil derivative, is effective against advanced non-small cell lung cancer (NSCLC) with mild toxicity and synergistic effects with radiation in preclinical trials. In this phase I study, we evaluated the dose-limiting toxicity and recommended dose of S-1 for a future phase II study when administered concurrently with thoracic radiation (total dose of 60Gy at 2Gy per daily fraction) in elderly patients (>75 years old) with localized advanced NSCLC. S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m2/day. Twenty-two previously untreated patients were enrolled in this study. Dose-limiting toxicity included febrile neutropenia, thrombocytopenia, stomatitis, and pneumonitis. One patient had grade 5 radiation pneumonitis. No other patient experienced radiation pneumonitis or esophagitis exceeding grade 2. The recommended dose for S-1 was determined to be 80mg/m2/day, which produced an overall response rate of 75{\%} (n=12). The median progression-free survival time was 11.5 months (95{\%} confidence interval: 7.1-15.8 months) with a median follow-up time of 27.9 months. These results indicate that concurrent treatment with S-1 and thoracic radiation is a feasible option for NSCLC in the elderly. A phase II study is currently under way.",
keywords = "Elderly, Non-small cell lung cancer, Radiation, S-1",
author = "Nagio Takigawa and Katsuyuki Kiura and Katsuyuki Hotta and Shinobu Hosokawa and Naoyuki Nogami and Keisuke Aoe and Kenichi Gemba and Keiichi Fujiwara and Shingo Harita and Mitsuhiro Takemoto and Kengo Himei and Tetsu Shinkai and Yoshirou Fujiwara and Saburo Takata and Masahiro Tabata and Susumu Kanazawa and Mitsune Tanimoto",
year = "2011",
month = "1",
doi = "10.1016/j.lungcan.2010.04.012",
language = "English",
volume = "71",
pages = "60--64",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer

AU - Takigawa, Nagio

AU - Kiura, Katsuyuki

AU - Hotta, Katsuyuki

AU - Hosokawa, Shinobu

AU - Nogami, Naoyuki

AU - Aoe, Keisuke

AU - Gemba, Kenichi

AU - Fujiwara, Keiichi

AU - Harita, Shingo

AU - Takemoto, Mitsuhiro

AU - Himei, Kengo

AU - Shinkai, Tetsu

AU - Fujiwara, Yoshirou

AU - Takata, Saburo

AU - Tabata, Masahiro

AU - Kanazawa, Susumu

AU - Tanimoto, Mitsune

PY - 2011/1

Y1 - 2011/1

N2 - S-1, an oral 5-fluorouracil derivative, is effective against advanced non-small cell lung cancer (NSCLC) with mild toxicity and synergistic effects with radiation in preclinical trials. In this phase I study, we evaluated the dose-limiting toxicity and recommended dose of S-1 for a future phase II study when administered concurrently with thoracic radiation (total dose of 60Gy at 2Gy per daily fraction) in elderly patients (>75 years old) with localized advanced NSCLC. S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m2/day. Twenty-two previously untreated patients were enrolled in this study. Dose-limiting toxicity included febrile neutropenia, thrombocytopenia, stomatitis, and pneumonitis. One patient had grade 5 radiation pneumonitis. No other patient experienced radiation pneumonitis or esophagitis exceeding grade 2. The recommended dose for S-1 was determined to be 80mg/m2/day, which produced an overall response rate of 75% (n=12). The median progression-free survival time was 11.5 months (95% confidence interval: 7.1-15.8 months) with a median follow-up time of 27.9 months. These results indicate that concurrent treatment with S-1 and thoracic radiation is a feasible option for NSCLC in the elderly. A phase II study is currently under way.

AB - S-1, an oral 5-fluorouracil derivative, is effective against advanced non-small cell lung cancer (NSCLC) with mild toxicity and synergistic effects with radiation in preclinical trials. In this phase I study, we evaluated the dose-limiting toxicity and recommended dose of S-1 for a future phase II study when administered concurrently with thoracic radiation (total dose of 60Gy at 2Gy per daily fraction) in elderly patients (>75 years old) with localized advanced NSCLC. S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m2/day. Twenty-two previously untreated patients were enrolled in this study. Dose-limiting toxicity included febrile neutropenia, thrombocytopenia, stomatitis, and pneumonitis. One patient had grade 5 radiation pneumonitis. No other patient experienced radiation pneumonitis or esophagitis exceeding grade 2. The recommended dose for S-1 was determined to be 80mg/m2/day, which produced an overall response rate of 75% (n=12). The median progression-free survival time was 11.5 months (95% confidence interval: 7.1-15.8 months) with a median follow-up time of 27.9 months. These results indicate that concurrent treatment with S-1 and thoracic radiation is a feasible option for NSCLC in the elderly. A phase II study is currently under way.

KW - Elderly

KW - Non-small cell lung cancer

KW - Radiation

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=78650195909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650195909&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2010.04.012

DO - 10.1016/j.lungcan.2010.04.012

M3 - Article

VL - 71

SP - 60

EP - 64

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -